Debt-to-equity of VYNE Therapeutics Inc. from 30 Sep 2018 to 30 Jun 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
VYNE Therapeutics Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Jun 2025.
  • VYNE Therapeutics Inc. Debt-to-equity for the quarter ending 30 Jun 2025 was 23%, a 61% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

VYNE Therapeutics Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q2 2025 23% +8.7% +61% 30 Jun 2025
Q1 2025 22% +5.7% +35% 31 Mar 2025
Q4 2024 17% -5.7% -25% 31 Dec 2024
Q3 2024 13% -25% -65% 30 Sep 2024
Q2 2024 14% -14% -50% 30 Jun 2024
Q1 2024 16% -5.5% -25% 31 Mar 2024
Q4 2023 23% +5.1% +28% 31 Dec 2023
Q3 2023 39% +18% +84% 30 Sep 2023
Q2 2023 28% +1.9% +7% 30 Jun 2023
Q1 2023 22% -24% -52% 31 Mar 2023
Q4 2022 18% -39% -68% 31 Dec 2022
Q3 2022 21% -52% -71% 30 Sep 2022
Q2 2022 27% -64% -71% 30 Jun 2022
Q1 2022 46% -46% -50% 31 Mar 2022
Q4 2021 57% -59% -51% 31 Dec 2021
Q3 2021 73% -57% -44% 30 Sep 2021
Q2 2021 90% -15% -14% 30 Jun 2021
Q1 2021 91% +3.7% +4.3% 31 Mar 2021
Q4 2020 116% +70% +153% 31 Dec 2020
Q3 2020 131% +116% +785% 30 Sep 2020
Q2 2020 105% +95% +883% 30 Jun 2020
Q1 2020 88% +80% +1028% 31 Mar 2020
Q4 2019 46% +39% +527% 31 Dec 2019
Q3 2019 15% +6.2% +73% 30 Sep 2019
Q2 2019 11% 30 Jun 2019
Q1 2019 7.8% 31 Mar 2019
Q4 2018 7.3% 31 Dec 2018
Q3 2018 8.6% 30 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.